<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-3</td>
<td>Letter of Welcome</td>
</tr>
<tr>
<td>P-4</td>
<td>ILCA 2021 Scientific Programme</td>
</tr>
<tr>
<td>P-14</td>
<td>Practicalities</td>
</tr>
<tr>
<td>P-15</td>
<td>Sponsors, Media and other Partners</td>
</tr>
<tr>
<td>P-17</td>
<td>About ILCA</td>
</tr>
<tr>
<td>P-18</td>
<td>Industry Sponsored Symposia</td>
</tr>
</tbody>
</table>
Dear ILCA members, colleagues, and friends,

It is our immense pleasure to invite you to attend the Virtual 15th Annual Conference of the International Liver Cancer Association (ILCA) from 2nd to 5th September 2021.

The Governing Board and the Education Committee of ILCA have worked over the year to bring together eminent experts from around the globe with the goal of improving our knowledge on liver cancer, from causes and mechanisms to prevention and patient care.

Virtually again this year, our broad community will have the opportunity to share knowledge, learn and network during four days around the latest advances in basic, translational, and clinical research on liver cancer.

The programme will provide you with a great educational experience and hopefully will allow you to interact with colleagues from different countries and with different research interests.

We look forward to welcoming you all virtually as we work together to advance liver cancer science and care to offer true hope to patients.

Warm regards,

On behalf of the ILCA Governing Board

Bruno Sangro, MD, PhD
ILCA President

Augusto Villanueva, MD, PhD
ILCA Executive Secretary
ILCA 2021 Scientific Programme

THURSDAY, 2 SEPTEMBER 2021 - CEST TIME

14:00 - 14:15
WELCOME ADDRESS

ILCA President, Bruno Sangro, MD, PhD (Spain)

14:15 - 16:15
RARE LIVER TUMORS PRE-CONFERENCE WORKSHOP

Chairs: Ghassan K. Abou-Alfa, MD (USA), Jessica Zucman-Rossi, MD, PhD (France)

• Fibrolamellar Carcinoma
  - Clinical aspects of fibrolamellar hepatocellular carcinoma
    Ghassan K. Abou-Alfa, MD (USA)
  - Basic/Translation aspects of fibrolamellar hepatocellular carcinoma
    Sanford Simon, PhD (USA)

• Cholangio Mix Tumor
  - Clinical management of mixed liver tumors
    Myron Schwartz, MD (USA)

• Hepatoblastoma
  - Clinical aspects of hepatoblastoma
    Tanya Trippett, MD (USA)
  - Basic aspect
    Jessica Zucman-Rossi, MD, PhD (France)

• Rare Hepatic Tumors
  - Rare hepatic tumors: What you need to know
    Valerie Paradis, MD, PhD (France)

• Patient Advocacy
  - Patient advocacy for patients with fibrolamellar HCC
    Mark Furth, PhD (USA)
THURSDAY, 2 SEPTEMBER 2021 - CEST TIME

16:45 - 17:45 SINGLE TOPIC WORKSHOP

• Molecular Diversity in HCC
  Amaia Lujambio, MD, PhD (USA), Andrew Zhu, MD, PhD (USA)

• Systemic Therapy
  Jean-Charles Nault, MD, PhD (France), Bristi Basu, MD, PhD (UK)

• Surgery in the management of HCC: Role of Surgeons and of the Radiologists
  Eric Vibert, MD, PhD (France), Lewis Roberts, MB, ChB, PhD (USA)

• Radiology
  Riccardo Lencioni, MD, EBIR, FSIR (Italy), Tae Kyoung Kim, PhD, FRCPC (Canada)

17:45 - 18:30 ILCA/EASL JOINT SYMPOSIUM

Chairs: Tim Meyer, BSc, MBBS, PhD, FRCP (UK), Maria Reig, PhD (Spain)

Speakers:

• CAR T Cell Therapy for HCC
  Mitchell Ho, PhD (USA)

• Innovative approached to CAR T Cell Therapy – lessons from haematology
  Claire Roddie, MD, PhD (UK)

• Identification of bacteria-derived HLA-bound peptides in melanoma
  Shelly Kalaoa, PhD (Germany)
BASIC STATE OF THE ART: TELOMERES AND CANCER

Chair: Amaia Lujambio, MD, PhD (USA)
Speaker:
- Telomere-induced DNA damage as anticancer strategy
  Maria Blasco, PhD (Spain)

YOUNG INVESTIGATOR SESSION

Chair: Laura Kulik, MD (USA)
Speakers:
4 oral presentations submitted by young researchers followed by Q&A time.
- O-01 Peroxiredoxin 2 drives NASH progression towards hepatocellular carcinoma by perturbing hepatic lipid metabolism
  Eugénie Schaeffer (France)
- O-02 Cabozantinib enhances anti-PD1 efficacy and elicits a neutrophil-based immune response in murine models: implications for human HCC
  Roger Esteban-Fabrò (Spain)
- O-03 Weight variations and level of estrogen exposure predict the evolution of hepatocellular adenomas
  Alix Demory (France)
- O-04 Immune profiling of hepatocellular carcinoma using deep-learning on histological slides
  Qinghe Zeng (USA)

TOP-SCORED POSTERS: BEST BASIC / TRANSLATIONAL POSTER SESSION

Chairs: Jessica Zucman-Rossi, MD, PhD (France), David Pinato, MD, PhD (UK)
Speakers:
- P-01 Temporal and Spatial Dynamics of Hepatic Stellate Cell Activation in Intrahepatic Cholangiocarcinoma.
  Liqin Zhu (USA)
- P-02 Intra-tumoral epigenetic heterogeneity and aberrant molecular clocks in hepatocellular carcinoma.
  Paula Restrepo (USA)
- P-03 Autoimmunity and cancer immunosurveillance in the biliary tree.
  Jonathan Pol (France)
- P-04 Inflamed class of HCC: an expansion of the immune class based upon new molecular features.
  Florian Castet (USA)
TOP-SCORED POSTERS: BEST BASIC / TRANSLATIONAL POSTER SESSION

- P-05 Phenotypic characteristics of the tumour microenvironment in primary and secondary hepatocellular carcinoma.  
  Petros Fessas (UK)
- P-06 New therapeutic targets in cisplatin-resistant hepatoblastoma.  
  Théo Hirsch (France)
- P-07 Notch Pathway Activation Drives Immune Evasion in Hepatocellular Carcinoma.  
  Katherine Lindblad (USA)
- P-09 Deep sequencing of HCC endothelium reveals an active role in immunosuppression and highlights the endo nucleotidase CD73 as a potential therapeutic target.  
  Rosemary Faulkes (UK)
- P-53 A humanized Claudin-1-specific monoclonal antibody for treatment of hepatocellular carcinoma.  
  Marion Muller (France)
- P-27 Increased hepatic pregnane X receptor protein expression negatively correlates with tight junction proteins and is a target for therapy in patients with hepatocellular carcinoma.  
  Balasubramaniyan Vairappan (India)

17:15 - 18:00  JUNIOR INVESTIGATOR AWARDS CEREMONY

In this session the International Liver Cancer Association is going to recognise 4 individuals for their outstanding contributions to advancing liver cancer research.

ILCA President: Bruno Sangro, MD, PhD (Spain)  
ILCA Executive Secretary: Augusto Villanueva, MD, PhD (USA)  
ILCA Treasurer: Tim Meyer, MD, PhD (UK)  
ILCA President Elect: Jessica Zucman-Rossi, MD, PhD (France)
**BASIC SCIENCE SYMPOSIUM: WHAT HAS SINGLE CELL GENOMICS CONTRIBUTED TO OUR UNDERSTANDING OF LIVER CANCER?**

*Chairs: Robert T. Schwabe, MD (USA), Amaia Lujambio, MD, PhD (USA)*

*Speakers:*

- **Single cell genomics and response to therapies in hepatocellular carcinoma**  
  Xin Wei Wang, PhD (USA)

- **Ploidy heterogeneity and HCC prevention**  
  Hao Zhu, MD, PhD (USA)

- **Tumor microenvironment in the development and progression of cholangiocarcinoma**  
  Silvia Affo, PhD (Spain)

**YOUNG INVESTIGATOR CLUB**

The ILCA Young Investigator Steering Committee (Y-ILCA) will present the main goals of this new young committee like promoting young investigators in ILCA, communicate the activities of ILCA to young investigators, build a young investigators active community and participate in the organization of activities for young investigators in ILCA educational activities, including the annual conference.

The Y-ILCA is composed by:

- **Laura Kulik**, USA - Governing Board mentor
- **David Pinato**, UK
- **Marina Bárěnca Varela**, USA
- **Marco Sanduzzi**, Spain
- **Monika Lewinska**, Denmark
- **Amanda Craig**, USA
- **Ken Liu**, Australia

Join the session and get to know more about the Y-ILCA committee and how you could participate on the activities by discussing with them.
ILCA 2021 Scientific Programme

SATURDAY, 4 SEPTEMBER 2021 - CEST TIME

12:45 - 13:00 DAILY WRAP-UP

Augusto Villanueva, MD, Phd (USA), Laura Kulik, MD (USA)

14:00 - 15:00 GENERAL SESSION 1: MOLECULAR PATHOGENESIS, CELL BIOLOGY, AND TRANSLATIONAL RESEARCH

Chairs: Stephanie Roessler, MD, PhD (Germany), Amaia Lujambio, MD, PhD (USA)

Speakers:
- O-05 Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma
  Philipp K. Haber (USA)
- O-06 A novel microenvironment-based classification of intrahepatic cholangiocarcinoma
  Daniela Sia (USA)
- O-07 Single-cell RNA sequencing unravels the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma
  Daniel Ho (USA)
- O-08 Cytokine Gradients in Human Hepatocellular Carcinoma Microenvironment Regulate Innate Lymphoid Cells
  Bernd Heinrich (Germany)

15:15 - 15:45 CLINICAL STATE OF THE ART: PAST, PRESENT, AND FUTURE OF TRANSPLANT ONCOLOGY

Chair: Gonzalo Sapisochin, MD, PhD (Canada)

Speaker:
- Past, present, and future of transplant oncology
  Vincenzo Mazzaferro, MD, PhD (Italy)

16:00 - 17:00 TOP-SCORED POSTERS: BEST CLINICAL POSTER SESSION

Chairs: Eric Vibert, MD, PhD (France), Maxime Ronot, MD, PhD (France)

Speakers:
- P-41 Early antibiotic exposure is not detrimental to response to immune checkpoint inhibitor therapy for hepatocellular carcinoma: evidence from an observational study.
  Petros Fessas (UK)
TOP-SCORED POSTERS: BEST CLINICAL POSTER SESSION

16:00 - 17:00

- P-42 A multicentred phase II clinical trial on serial combination of Yttrium 90-resin microspheres (Y90-RE) and chemotherapy for locally advanced intra-hepatic cholangiocarcinoma (ICC).
  Stephen Lam Chan (China)

- P-38 Impact of metabolic syndrome and non-alcoholic fatty liver disease in outcomes and tolerance after percutaneous multibipolar radiofrequency ablation for early hepatocellular carcinoma.
  Thi Thu Nga Nguyen (France)

- P-34 Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON.
  Masatoshi Kudo (Japan)

- P-36 A Pilot Study of the combination of Immune Checkpoint Inhibition with Ablation in Subjects with Hepatocellular Carcinoma: an evaluation of Trans-arterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA).
  Rebecca Wetzel (USA)

- P-20 Characteristics and survival of hepatocellular carcinoma in non-cirrhotic liver: A Spanish multicentre study.
  Sonia Pascual (Spain)

- P-21 Prognosis of patients with other primary tumors associated to hepatocellular carcinoma.
  Miriam Celada-Sendino (Spain)

- P-55 Lifestyle changes in DAA-cured Hepatitis C patients with advanced liver disease included in a nurse-led liver cancer screening program.
  Gemma Iserte (Spain)

- P-29 Dual filtration system for isolation and single cell RNA sequencing of circulating tumor cells and clusters in hepatocellular carcinoma: A pilot study.
  Vincent Chen (USA)

17:15 - 18:00

ILCA TUMOR BOARD

Chair: Augusto Villanueva, MD, PhD (USA)

Speaker:
- Case 1 HCC
- Case 2 Cholangiocarcinoma

Pierre Nahon, MD, PhD (France)

Panel of experts:
- Sasan Roayaie, MD, FACS (USA)
- Ann-Lii Chen, MD, PhD (Taiwan)
- Thierry Debaere, MD (France)
- Angela Lamarca, MD, PhD, MSc (Spain)
ILCA 2021 Scientific Programme

SATURDAY, 4 SEPTEMBER 2021 - CEST TIME

17:15 - 18:00 GENERAL SESSION 2: EPIDEMIOLOGY, STAGING AND PROGNOSIS

Chairs: David Pinato, MD, PhD (UK), Anjana Pillai, MD (USA)

Speakers:

• O-09 Characteristics of unresectable HCC patients in the new era of immunotherapy: first results from the ELITor study, based on the French prospective multicenter CHIEF cohort.
  Eric Nguyen-Khac (France)

• O-10 Mailed Outreach Strategy Significantly Increases Hepatocellular Carcinoma Surveillance Utilization: A Multi-Site Randomized Clinical Trial.
  Amit Singal (USA)

• O-11 Cachexia is Prevalent in Patients with Hepatocellular Carcinoma and Associated with Worse Prognosis.
  Nicole Rich (USA)

• O-12 ERS: A simple, user-friendly model to predict early recurrence after surgical resection for hepatocellular carcinoma.
  Charlotte Constantin (France)

• O-13 The Association of Sustained Virologic Response on Outcomes in Patients with Hepatocellular Carcinoma with Hepatitis C.
  Neehar Parikh (USA)

• O-14 A Prognostic Score Using Gadoxetic Acid–enhanced MRI To Predict Overall Survival After Curative Resection For Hepatocellular Carcinoma.
  Hong Wei (China)
ILCA 2021 Scientific Programme

SUNDAY, 4 SEPTEMBER 2021 - CEST TIME

12:45 - 13:00  DAILY WRAP-UP

Augusto Villanueva, MD, Phd (USA), Amaia Lujambio, MD, PhD (USA)

14:00 - 15:30  GENERAL SESSION 3: DIAGNOSIS, IMAGING AND BIOMARKERS

Chairs: Amit Singal, MD (USA), Nicole Rich, MD, MSCS (USA)

Speakers:

- O-15 Detection of Early-Stage HCC by Abbreviated MRI: Multicenter Validation Against Surgical Pathology. Takeshi Yokoo (USA)
- O-16 Limitations of non-invasive radiological criteria for the diagnosis of advanced hepatocellular carcinoma. Alexa Childs (UK)
- O-17 Hepatocellular carcinoma early detection using Magnetic Resonance Imaging is cost-effective in French high-risk patients with cirrhosis. Pierre Nahon (France)
- O-18 Imbrave150: Albumin-Bilirubin (ALBI) grade analyses in a phase III study of Atezolizumab (ATEZ0) + Bevacizumab (BEV) versus Sorafenib (SOR) in patients (PTS) with unresectable Hepatocellular Carcinoma (HCC). Masatoshi Kudo (Japan)
- O-19 Circulating Tumor Cell-Based mRNA Scoring System for Prognostication of Hepatocellular Carcinoma - Translating HCC Tissue-based mRNA Profiling into a Non-invasive Setting. Yi-Te Lee (USA)
- O-20 Undernutrition in patients with primary hepatocellular carcinoma. Hitomi Takada (Japan)

15:45 - 16:45  ILCA DEBATES

Chair: Richard Finn, MD (USA)

- HCC down-staging to surgical therapies
  - Plenty of room
    Laura Crocetti, MD, PhD, EBIR (Italy)
  - Still too many questions
    Laura Kulik, MD (USA)

- Early transition to systemic therapies in patients at stage BCLC-B
  - Too early to recommend
    Jens Ricke, MD (Germany)
  - It is time to transition systemic therapy to BCLC stage B
    Lipika Goyal, MD (USA)
SUNDAY, 4 SEPTEMBER 2021 - CEST TIME

16:45 - 18:00 CLINICAL SCIENCE SYMPOSIUM: THE FUTURE OF COMBINATION THERAPIES IN HCC

Chairs: Lorenza Rimassa, MD, PhD (Italy), Stephen Lam Chan, MD (Hong-Kong)

Speakers:

- Triple systemic therapies in HCC: Rationale, prospects and ongoing trials
  Robin Kate Kelley, MD (USA)

- Combination therapies and adverse events: pearls in clinical management
  David Pinato, MD, PhD (UK)

- Clinical trials design in area or immune therapies: AASLD consensus
  Josep Maria Llovet, MD, PhD (USA)

18:15 - 19:45 GENERAL SESSION 4: THERAPY & CLINICAL TRIALS IN 2021

Chairs: Robin Kate Kelley, MD (USA), Ann-Lii Chen, MD, PhD (Taiwan)

Speakers:

- O-21 Nivolumab (NIVO) in sorafenib (SOR)-naive and -experienced patients with advanced hepatocellular carcinoma (aHCC): 5-year follow-up from CheckMate 040 cohorts 1 and 2.
  Joerg Trojan (Germany)

- O-22 Data from the third dose cohort and expansion phase of a Phase 1 trial of ADP-A2AFP SPEAR T-cells for patients with hepatocellular carcinoma and other cancer types expressing alpha-fetoprotein.
  Bruno Sangro (Spain)

- O-23 Treatment-related toxicity and improved outcomes with immune checkpoint inhibitors in patients with hepatocellular carcinoma.
  David Pinato (UK)

- O-24 Tailored approach for the treatment of hepatocellular carcinoma within Milan criteria developed on advanced fibrosis/cirrhosis by multibipolar radiofrequency ablation or liver resection: a retrospective multicentric study on 1060 patients.
  Jean-Charles Nault (France)

  Ho Yeong Lim (South Korea)

- O-26 Systematic review and meta-analysis of RCT (2002-2020): is etiology relevant for immunotherapies?
  Philipp K. Haber (USA)

19:45 - 20:00 FAREWELL ADDRESS

ILCA President 2021-2023, Jessica Zucman-Rossi, MD, PhD (France)
 Practicalities  

ABOUT THE CONFERENCE  

• ILCA

The International Liver Cancer Association (ILCA) is the only international organisation devoted exclusively to liver cancer research for experts from all related disciplines. ILCA aims at creating an international multidisciplinary forum to address the increasing incidence of liver cancer through the enhancement of the knowledge of clinical, translational, and basic research, ultimately creating novel preventive, diagnostic and therapeutic strategies. The purpose for which ILCA was established is the advancement of medical education, research, and clinical care in the field of liver cancer.

Please come and visit us at the ILCA virtual booth. The ILCA Team will be pleased to meet you and provide you with any information you may want to know on ILCA activities, membership, and future ILCA events.

• Accreditation

The International Liver Cancer Association’s 15th Annual Conference being the second ILCA virtual conference this year has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 15 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she spent in the educational activity.

• Junior Investigator Awards

ILCA will recognise extraordinary achievements in liver cancer research across disciplines and support the professional development of four junior investigators in training. The awards will be given for novel and significant liver cancer research across the fields of basic cancer research, translational cancer research, cancer diagnosis, the prevention of cancer, or cancer patients treatment.

• Official Language

The official language of the conference is English. Simultaneous translation will not be provided.

Information is also available at www.ilca-online.org
Sponsors, Media and other Partners

ILCA warmly thanks all the sponsors for their involvement in ILCA 2021

Supporters

Principal Sponsor

Eisai

Conference Sponsors

BAYER
Boston Scientific
Bristol Myers Squibb
Incyte
IPSEN
Roche

Conference Supporters

AstraZeneca
EXELIXIS
SIRTeX

ILCA Industry Partners

Eisai
IPSEN
Roche
Guerbet
Sponsors, Media and other Partners

Media Partners

- ALEH
- Dovepress
- EMJ
- ESSO
- International Liver Transplantation Society (ILTS)
- Touch Oncology

Partner Societies

- American Association for the Study of Liver Diseases (AASDL)
- American Society of Clinical Oncology (ASCO)
- Argentinian Society of Hepatology (SAHE)
- Asian Pacific Association for the Study of the Liver (APASL)
- Asia-Pacific Primary Liver Cancer Expert Association
- Canadian Association of Gastroenterology (CAG)
- Canadian Association for the Study of the Liver (CASL)
- Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
- European-African Hepato-Pancreato-Biliary Association (E-AHPBA)
- European Association for Cancer Research (EACR)
- European Association for the Study of the Liver (EASL)
- European Society for Medical Oncology (ESMO)
- European Society of Surgical Oncology (ESSO)
- French Association for the Study of the Liver (AFEF)
- International Liver Transplantation Society (ILTS)
- Japan Society of Clinical Oncology (JSCO)
- Japanese Society of Medical Oncology (JSMO)
- Korean Association for Clinical Oncology (KACO)
- Korean Association for the Study of the Liver (KASL)
- Korean Cancer Association (KCA)
- Korean Liver Cancer Association (KLCA)
- Korean Association of Hepato-Biliary-Pancreatic Surgery (KAHBPS)
- Latin American Association for the Study of the Liver (ALEH)
- Liver Transplant Society of India (LTSI)
- Society of Interventional Oncology (SIO)
- Stockholm Liver Week
- United European Gastroenterology (UEG)
About ILCA

Liver cancer is rapidly increasing worldwide, triggering widespread interest and strong focus surrounding all aspects of this disease. Given the naturally multidisciplinary nature of liver cancer, however, no single association has before the International Liver Cancer Association (ILCA) adopted a transversal approach to liver cancer by connecting expertise from interrelated fields, research and treatment levels. In response to this shortfall, ILCA was established in 2006 and is currently the only international organisation devoted exclusively to liver cancer across disciplines.

Our Mission
ILCA strives to advance research in the pathogenesis, prevention, and treatment of liver cancer, by promoting novel pathogenic, diagnostic, and therapeutic interventions for liver cancer, and taking a transversal approach to research. Indeed, ILCA brings together scientists, physicians and allied professionals from all interrelated fields and countries and strives to welcome and incorporate individuals involved in all the scientific disciplines devoted to basic, translational and clinical research in liver cancer as individual members. ILCA actively partners with other professional associations involved in any aspect related to liver cancer research, with the objective to join efforts for the benefit of science.

Joining Our Community
We invite you to discover more about ILCA on www.ilca-online.org, as well as to connect with our expanding group of interested physicians, scientists, and allied health professionals from various fields and from around the world.

Membership to ILCA not only provides you with exclusive benefits such as reduced registration rates to our events, exciting networking and educational opportunities and active involvement in association affairs; it also helps us to develop our activities and our reach to advance liver cancer research and care.

ILCA Governing Board

<table>
<thead>
<tr>
<th>Executive Committee</th>
<th>Council</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Sasan Roayaie, USA</td>
</tr>
<tr>
<td>Bruno Sangro, Spain</td>
<td>Laura Kulik, USA</td>
</tr>
<tr>
<td>Executive Secretary</td>
<td>Jeong Min Lee, Republic of Korea</td>
</tr>
<tr>
<td>Augusto Villanueva, USA</td>
<td>Amit Singal, USA</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Eric Vibert, France</td>
</tr>
<tr>
<td>Tim Meyer, UK</td>
<td>Amaia Lujambio, USA</td>
</tr>
<tr>
<td>President Elect</td>
<td>Michiie Sakamoto, Japan</td>
</tr>
<tr>
<td>Jessica Zucman-Rossi, France</td>
<td>Lorenza Rimassa, Italy</td>
</tr>
<tr>
<td></td>
<td>R. Kate Kelley, USA</td>
</tr>
<tr>
<td></td>
<td>Stephen Chan, Hong Kong</td>
</tr>
</tbody>
</table>

www.ilca2021.org  I  www.ilca-online.org
Industry Sponsored Symposia

Industry Symposia at ILCA 2021 give you the chance to discuss and exchange knowledge on data and products with our industry sponsors.

THURSDAY, SEPTEMBER 2, 2021

18:45 - 19:45 CET  INCYTE INDUSTRY SPONSORED SYMPOSIUM

*Time for Precision Medicine for Patients with Cholangiocarcinoma*

The esteemed faculty will give their expert perspectives on cholangiocarcinoma (CCA), including the burden of disease, considerations around molecular profiling and the emergence of precision medicine for patients with advanced CCA.

**Speakers:**
- **Professor Bruno Sangro, MD, PhD; Clinica Universidad de Navarra, Pamplona, Spain**
- **Dr Cindy Neuzillet, MD, PhD; Institut Curie, Saint Cloud, Paris, France**
- **Professor Albrecht Stenzinger, MD; University Hospital Heidelberg, Heidelberg, Germany**
- **Dr Joachim Mertens, MD; University Hospital Zürich, Zürich, Switzerland**

19:45 - 20:45 CET  ROCHE INDUSTRY SPONSORED SYMPOSIUM

*Making waves in unresectable HCC: a new standard of care?*

Recent approvals and emerging data with cancer immunotherapy combinations have inspired new optimism in the landscape of unresectable HCC, with the changing tide reaching beyond clinical trial centres and into everyday practice. With novel treatment strategies now available, we must focus on optimising the patient experience. Deep diving into updated data, exploratory subgroup analyses and a real-world patient case, we will provide expert insight and guidance on what clinicians need to know in order to make informed and tailored treatment decisions.

**Speakers:**
- **Professor Bruno Sangro, MD, PhD; Clinica Universidad de Navarra, Pamplona, Spain**
- **Lorenza Rimassa, Associate Professor of Medical Oncology; Humanitas University and IRCCS Humanitas Research Hospital, Italy**

FRIDAY, SEPTEMBER 3, 2021

13:00 - 14:00 CET  BAYER INDUSTRY SPONSORED SYMPOSIUM

*Treating Beyond Clinical Trials: Connecting Real-world Data on Sorafenib and Regorafenib to Clinical Experience*

With the increasing complexity of the unresectable HCC treatment landscape, therapeutic choices are becoming more and more challenging, particularly for those subgroups of patients who are commonly seen in clinical practice but who are typically excluded from clinical trials. Our global panel of experts will explore the nuances of treatment choice in these patients and engage with the data that supports the different therapeutic options.

**Speakers:**
- **Markus Peck-Radosavljevic, MD, MBA; Klinikum Klagenfurt am Wörthersee, Austria**
- **Pierre Gholam, MD, FAASLD, AGAF; Case Western Reserve University, United States**
- **Madappa Kundranda, MD, PhD; Banner MD Anderson Cancer Center, United States**
- **Changhoon Yoo, MD; University of Ulsan College of Medicine, Korea**

Industry Symposia at ILCA 2021 give you the chance to discuss and exchange knowledge on data and products with our industry sponsors.
Industry Sponsored Symposia

SATURDAY, SEPTEMBER 4, 2021

13:00 - 14:00 CET

EISAI INDUSTRY SPONSORED SYMPOSIUM

The role of first-line monotherapy in a uHCC combination market

A panel of leading experts will discuss the role of LENVIMA® (lenvatinib) monotherapy in a rapidly evolving treatment landscape, followed by a live Q&A. With combination therapies expected to become the standard of care in first-line uHCC, our panel will cover a variety of topics including patient selection, clinical considerations, and the latest real-world evidence.

Speakers:
- **Professor Josep Llovet**, Professor of Research-ICREA, Liver Unit, IDIBAPS-Hospital Clinic of Barcelona (Spain) and Director of the Liver Cancer Program and Full Professor of Medicine at Mount Sinai School of Medicine, New York, USA.
- **Dr Stephen Chan**, Associate (Clinical) Professor at the Department of Clinical Oncology of the Chinese University of Hong Kong.
- **Professor Arndt Vogel**, Professor for gastrointestinal oncology at the Hannover Medical School

SUNDAY, SEPTEMBER 5, 2021

13:00 - 14:00 CET

BOSTON SCIENTIFIC INDUSTRY SPONSORED SYMPOSIUM

Evidence & Clinical Application of SIRT in Early & Intermediate HCC

Beginning with more advanced stage patients to early-stage HCC with low tumour burden. From bridging and downstaging to lobectomy and segmentectomy, the versatility of TheraSphere has been proven in more than 50 publications, and more data is on its way...

Speakers:
- **Professor Eric Vibert**, Liver Surgeon, Paul Brousse Hospital, Villejuif, France
- **Professor Daniel Seehofer**, HPB Surgeon, Universitätsklinikum Leipzig, Leipzig, Germany
- **Professor Juliene Edeline**, Medical Oncologist, Centre Eugène Marquis, Rennes, France
- **Professor Jens Theysohn**, Interventional Radiologist, Universitätsklinikum Essen, Essen, Germany

 Disclaimer

This ILCA Annual Final Brochure has been produced using author-supplied copies. Editing has been restricted to minor spelling corrections where appropriate, otherwise every effort has been made to reproduce the abstracts as originally submitted. The organiser and publishers assume no responsibility for any injury and/or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. In view of rapid advances in medical sciences, independent verification of diagnoses and drug doses is recommended.